Clinical trials: Metastasis Colorectal Cancer
Metastatic Colorectal Cancer
An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to examine the correlation between UGT1A1 genotypes and the efficacy of CPT-11 based regimens (FOLFIRI, CPT-11+S-1, CPT-11) for patients with metastatic colorectal cancer.
- Trial name
- NCT01039506
- Testing
- CPT-11 based regimens
- Where
- Japan
- Volunteers
- 1,376 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Metastatic Colorectal Cancer
Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer
A growing amount of reports has consistently evidenced that a sustained inhibition of the angiogenesis is an effective therapeutic strategy, able to improve the outcome of metastatic colorectal cancer (mCRC) patients.
- Trial name
- CIRCUS (NCT02623621)
- Testing
- chemotherapy plus bevacizumab
- Where
- Italy
- Volunteers
- 103 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Colorectal Neoplasms
MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer
The purpose of the study is to determine the feasibility of generating sufficient MicroOrganoSpheres (MOS) from a biopsy of a subject's adenocarcinoma of the colon and/or rectum that is metastatic to the liver and completing a…
- Trial name
- MODEL-CRC (NCT05189171)
- Testing
- MicroOrganoSphere (MOS) drug screen
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- Xilis, Inc.
Colon Cancer, Lymphatic Metastasis
Sentinel Node Mapping With Indocyanine Green in Colon Cancer: a Feasibility Trial and a Descriptive Serie.
This study is a clinical feasibility trial that will contribute to the clarification of whether sentinel node mapping with indocyanine green (ICG) provides a better basis for staging of colorectal cancer.
- Trial name
- SENSE (NCT02167087)
- Testing
- Sentinel node mapping
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Ismail Gögenür
Colonic Neoplasms
Enzastaurin for Patients With Metastatic Colorectal Cancer
Enzastaurin given daily to participants with colorectal cancer who have Stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer
- Trial name
- NCT00192114
- Testing
- Enzastaurin HCl
- Where
- 3 sites in Denmark, Sweden
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer
LYL273 for Patients With Relapsed or Refractory mCRC
This is a Phase 1/2 open-label, multicenter study evaluating the safety and efficacy of LYL273 in participants with relapsed or refractory metastatic colorectal cancer.
- Trial name
- CARABiNER (NCT05319314)
- Testing
- LYL273
- Where
- 5 sites in United States
- Volunteers
- 155 people
- Sponsor
- Lyell Immunopharma, Inc.
To Compare the Monitoring of Circulating Tumor DNA With the Efficacy of Chemotherapy Evaluated by Computer Tomography Scan.
Analysis of Circulating Tumor DNA to Monitor Metastatic Colorectal Cancer Treatment
Colorectal cancer (CRC) is the third of the most common cancers and the second leading cause of cancer death in western countries.
- Trial name
- NCT01983098
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colorectal Cancer, Liver Metastases
Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM
The primary objectives of this phase I/II, prospective clinical trial, are to assess the optimal dose, efficacy, safety and immunological effect of ablation and intra-tumoral injection of a novel immuno-adjuvant (IP-001) for…
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer
- Trial name
- INJECTABL-II (NCT06630624)
- Testing
- IP-001
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- M.R. Meijerink
Metastatic Colorectal Cancer, RAS Mutation
Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer
A phase II clinical study of Sintilimab (IBI308) combined with Bevacizumab, Oxaliplatin and Capecitabine regimen as first-line treatment in patients with RAS-mutant and microsatellite stable metastatic colorectal cancer.
- Conditions
- Metastatic Colorectal Cancer, RAS Mutation, Microsatellite Stable
- Trial name
- NCT04194359
- Testing
- Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Cancer, Metastatic Cancer
Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with surgery may kill more tumor cells.
- Trial name
- NCT00006479
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- 111 sites in Australia, Austria and 11 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00008060
- Testing
- FOLFIRI regimen, FOLFOX regimen, fluorouracil
- Where
- United Kingdom
- Sponsor
- Medical Research Council
Metastatic Colorectal Cancer, mCRC
The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation
The purpose of this study was to assess efficacy, safety and PK in metastatic colorectal cancer (mCRC) given HLX208 (BRAF V600E inhibitor).
- Trial name
- NCT05127759
- Testing
- HLX208
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Henlius Biotech
Patients With Advanced Metastatic Colorectal Cancer
Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC
A Phase II Study to Assess the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and SBRT as A third-line and Posterior Line Treatment in Patients With Advanced Colorectal Cancer
- Trial name
- NCT04924179
- Testing
- Tislelizumab plus Fruquintinib and SBRT
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Huazhong University of Science and Technology
Colorectal Cancer, Liver Metastases
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
The primary objective of this study is to assess whether the addition of Serplulimab (a PD-1 inhibitor) and Bevacizumab (an anti-angiogenesis agent) to the standard FOLFOX chemotherapy can enhance the immune microenvironment in…
- Trial name
- NCT06280495
- Testing
- Oxaliplatin, Fluorouracil, Serplulimab
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Sun Yat-sen University
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Recurrent Colon Cancer, Recurrent Rectal Cancer
2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer
This pilot phase II studies how well computed tomography (CT) and positron emission tomography (PET) imaging works in detecting disease in patients undergoing surgery for metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV A Bladder Cancer, Stage IV A Rectal Cancer
- Trial name
- NCT01821105
- Testing
- PET Scan, CT Scan, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Colo-rectal Cancer
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
The purpose of this study is to determine the immunogenicity of the CIMAvaxEGF® vaccine (that is, its effectiveness in inducing an anti-tumor immune response) in patients with metastatic KRAS/NRAS/BRAF wild-type gene colorectal…
- Trial name
- NCT06011772
- Testing
- Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine, Leucovorin, Oxaliplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Advanced Cancer, Metastatic Cancer
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Colon, Malignant Neoplasm of Lung
- Trial name
- NCT04975256
- Testing
- MRTX849, BI 1701963
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Mirati Therapeutics Inc.
Undefined
Study on the Impact of a Modified Mediterranean Diet, in Patients With Colorectal Cancer Undergoing Active Medical Oncology Treatment
The study plans to evaluate the impact of the Modified Mediterranean Diet on the biodiversity of the intestinal microbiota (the set of physiological bacteria present at the intestinal level) in patients suffering from metastatic…
- Trial name
- MIC-1 (NCT06794931)
- Testing
- Nutrition, Biological samples collection
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Socio Sanitaria della Brianza
Liver Metastases
CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
This is an open label fixed dose phase Ib of anti-CEA CAR-T cells hepatic artery infusions and yttrium-90 SIR-Spheres in patients with CEA-expressing liver metastases.
- Trial name
- HITM-SIR (NCT02416466)
- Testing
- anti-CEA CAR-T cells, Sir-Spheres
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Roger Williams Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.